6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Autor: Xavier Pivot, Gilles Romieu, Marc Debled, Jean-Yves Pierga, Pierre Kerbrat, Thomas Bachelot, Alain Lortholary, Marc Espié, Pierre Fumoleau, Daniel Serin, Jean-Philippe Jacquin, Christelle Jouannaud, Maria Rios, Sophie Abadie-Lacourtoisie, Laurence Venat-Bouvet, Laurent Cany, Stéphanie Catala, David Khayat, Laetitia Gambotti, Iris Pauporté, Celine Faure-Mercier, Sophie Paget-Bailly, Julie Henriques, Jean Marie Grouin, C Piprot, L Cals, L Chaigneau, F Demarchi, T N'Guyen, U Stein, C Villanueva, JL Bréau, AK Chouahnia, P Saintigny, F Boué, P deSaint-Hilaire, I Guimont, N Grossat, B Valenza, E Lévy, J Médioni, C Delbaldo, J Grenier, D Pouessel, S Lavau-Denès, C Falandry, C Fournel-Fédérico, G Freyer, S Tartas, V Trillet-Lenoir, F Bons, G Auclerc, S Chièze, N Raban, C Tournigand, S Trager-Maury, G Bousquet, C Cuvier, S Giacchetti, A Hocini, C LeMaignan, JL Misset, D Avenin, C Beerblock, J Gligorov, P Rivera, H Roché, P Bougnoux, N Hajjaji, O Capitain, R Delva, P Maillart, P Soulié, H Bonnefoi, M Durand, N Madranges, L Mauriac, P Chollet, AF Dillies, X Durando, JP Ferrière, C Mouret-Reynier, JM Nabholtz, I Van Praagh, P Cottu, V Diéras, A Durieux, M Galotte, V Girre, S Henry, I Iurisci, M Jouve, V Laurence, L Mignot, S Piperno-Neumann, P Tresca, B Coudert, E Ferrant, F Mayer, AC Vanneuville, J Bonneterre, V Servent, L Vanlemmens, P Vennin, JP Guastalla, P Biron, L Dupuy-Brousseau, L Lancry, I Ray-Coquard, P Rebattu, O Trédan, JM Extra, F Rousseau, C Tarpin, M Fabbro, E Luporsi, L Uwer, B Weber, D Berton-Rigaud, E Bourbouloux, M Campone, JM Ferrero, P Follana, R Largillier, V Mari, B Costa, H Curé, JC Eymard, N Jovenin, D Lebrun, J Meunier, G Yazbek, D Gedoin, B Laguerre, C Lefeuvre, E Vauléon, A Chevrier, C Guillemet, M Leheurteur, O Rigal, I Tennevet, C Veyret, E Brain, M Guiterrez, F Mefti-Lacheraf, T Petit, F Dalenc, L Gladieff, F André, S Delaloge, J Domont, J Ezenfis, M Spielmann, P Guillet, V Boulanger, J Provençal, L Stefani, C Alliot, D Ré, C Bellaiche-Miccio, G Boutan-Laroze, R Vanica, P Dion, G Sadki-Benaoudia, A Marti, AL Villing, B Slama, JL Dutel, S Nguyen, R Saad, O Arsène, Z Merad-Boudia, H Orfeuvre, J Egreteau, MJ Goudier, R Lamy, B Leduc, C Sarda, B Salles, C Agostini, I Cauvin, A Dufresne, M Mangold, S Lebouvier-Sadot, B Audhuy, JC Barats, S Cluet-Dennetière, D Zylberait, G Netter, L Gautier-Felizot, I Cojean-Zelek, A Plantade, S Vignot, E Guardiola, P Marti, I deHartingh, R Diab, A Dietmann, S Ruck, C Portois, S Oddou-Lagranière, F Campos-Gazeau, A Bourcier, F Priou, JF Geay, D Mayeur, P Gabez, R ElAmarti, M Combe, P Raichon-Patru, P Amsalhem, J Dauba, D Paraiso, F Guinet, B Duvert, M Litor, F Kara-Slimane, A Bichoffe, N Denizon, P Soyer, F Morvan, S Van-Hulst, L Vincent, C Alleaume, P Ibanez-Martin, A Youssef, Z Tadrist, E Carola, C Pourny, JF Toccanier, N Al-Aukla, K Mahour-Bacha, J Salvat, P Nouyrigat, S Clippe, MC Gouttebel, L Vedrine, G Clavreul, O Collard, D Mille, Y Goubely, R Hervé, S Kirscher, F Plat, V Delecroix, V Ligeza-Poisson, D Coeffic, D Fric, C Garnier, C Leyronnas, T Kreitman, E Teissier, P Martin, S Rohart deCordoue, C ElKouri, JF Ramée, C Laporte, O Bernard, T Altwegg, A Darut-Jouve, JP Dujols, F Darloy, C Giraud, V Pottier-Kyndt, N Achour, S Drony, M Moriceau, C Sarrazin, JC Legueul, J Mandet, D Besson, AC Hardy-Bessard, J Cretin, P Houyau, E Achille, D Genêt, H Thévenot, A Moran-Ribon, JM Pavlovitch, P Ardisson, I Moullet, B Couderc, V Fichet, F Burki, A Auliard, CB Levaché, P Cailleux, F Schaeffer, N Albin, D Sévin-Robiche, J Domas, S Ellis, P Montcuquet, GA Baumont, M Bégue, S Gréget, JL Ratoanina, A Vanoli, C Bielsa, M Bonichon-Lamichhane, D Jaubert, H Laharie-Mineur, L Alcaraz, E Legouffe, H Bourgeois, G Cartron, F Denis, O Dupuis, G Ganem, S Roche-Forestier, L Delzenne, E Chirat, JL Baticle, E Béguier, S Jacquot, E Janssen, H Lauché, A LeRol, JP Chantelard, GA L'Helgoualc'h, EC Antoine, A Kanoui, JF Llory, JM Vannetzel, J Vignoud, C Bruna, T Facchini, K Moutel-Corviole, A Voloch, A Ghoul, D Loiseau, N Barbet, N Dohollou, K Yakendji

Publikováno v: Lancet (London, England). 393(10191)

Summary Background In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial could not show that 6 months of adjuvant trastuzumab was non-inferior to 12 months. Here, we report the planned fin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a38de46b67775457b35c99536d038418
https://pubmed.ncbi.nlm.nih.gov/31178155

Chimioradiothérapie concomitante des cancers du sein inflammatoire, non métastatiques, non répondeurs à une chimiothérapie première

Autor: P. Gimbergues, G. Lebouedec, J.-L. Achard, C. Pomel, S. Dubois, C. Benoît, I. Van Praagh-Doreau, A. Bellière-Calandry, J. Moreau, Michel Lapeyre, G. Loos, M.-A. Mouret-Reynier

Publikováno v: Cancer/Radiothérapie. 19:739-745

Resume Objectif de l’etude Apres l’echec d’une chimiotherapie initiale d’un cancer du sein inflammatoire et lorsque la chirurgie est impossible, une chimioradiotherapie concomitante peut etre proposee. Patientes et methodes Dix patientes atte

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::80cb3eef4f85819dd94cec5fce3a9aab
https://doi.org/10.1016/j.canrad.2015.06.020

Indications, contre–indications, résultats attendus et choix de la chimiothérapie néo–adjuvante du cancer du sein opérable

Autor: Hervé Curé, P. Chollet, S. Amat, I. Van Praagh, J. P. Ferriere, M.-A. Mouret–Reynier, Catherine Abrial

Publikováno v: ONCOLOGIE. 6:187-192

La chimiotherapie neoadjuvante du cancer du sein correspond a l’utilisation d’un traitement cytostatique systemique avant le traitement locoregional (chirurgie et/ou radiotherapie). Initiee dans les annees 1970 pour le traitement des formes local

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::aba19880882aa53ff71b090a9ead8fc4
https://doi.org/10.1007/s10269-004-0054-3

Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer

Autor: J M, Nabholtz, N, Chalabi, N, Radosevic-Robin, M M, Dauplat, M A, Mouret-Reynier, I, Van Praagh, V, Servent, J P, Jacquin, K E, Benmammar, S, Kullab, M R K, Bahadoor, F, Kwiatkowski, A, Cayre, C, Abrial, X, Durando, Y J, Bignon, P, Chollet, F, Penault-Llorca

Publikováno v: International journal of cancer. 138(9)

Systemic therapy for triple negative breast cancer (TNBC) is mostly based upon chemotherapy. Epithelial Growth Factor Receptor (EGFR) is overexpressed in around 50% of TNBC and may play a role in its pathogenesis. Consequently, we performed a multice

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c3f2f87641f5c27ac684d1adb00a7231
https://pubmed.ncbi.nlm.nih.gov/26649807

Clinical and pathological response to primary chemotherapy in operable breast cancer

Autor: J.L. Misset, P. Chollet, I. van Praagh, Sabine Charrier, E. Brain, Hervé Curé, J. P. Ferriere, V. Feillel, Jacques Dauplat, M. De Latour

Publikováno v: European Journal of Cancer. 33:862-866

Neoadjuvant chemotherapy is used to improve patients' survival in locally-advanced and inflammatory breast cancer and to increase conservative surgical procedures in bulky tumours. Pathological complete responses are unusual. The aim of this pilot st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1854117eda633346d24998c4f7c53f5
https://doi.org/10.1016/s0959-8049(97)00038-5